GSA Capital Partners’s AC Immune ACIU Stock Holding History

GSA Capital Partners’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32K	Buy	+11,530	New	+$35.8K	﹤0.01%	1626
2022 Q1	–	Sell	-73,046	Closed	-$362K	–	1362
2021 Q4	$362K	Buy	+73,046	New	+$425K	0.05%	807
2020 Q2	–	Sell	-16,800	Closed	-$116K	–	580
2020 Q1	$116K	Sell	16,800 -15,300	-48%	-$120K	0.03%	875
2019 Q4	$273K	Buy	32,100 +3,500	+12%	+$23.3K	0.03%	1086
2019 Q3	$142K	Buy	+28,600	New	+$153K	0.02%	1234
2018 Q4	–	Sell	-13,801	Closed	-$110K	–	1301
2018 Q3	$110K	Buy	+13,801	New	+$139K	0.01%	1548
2017 Q2	–	Sell	-50,697	Closed	-$525K	–	1639
2017 Q1	$525K	Buy	50,697 +15,464	+44%	+$190K	0.03%	1067
2016 Q4	$457K	Buy	+35,233	New	+$488K	0.03%	1047

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GSA Capital Partners's ACIU Position: Q1 2026 in Review

GSA Capital Partners opened a new position in AC Immune (ACIU) in Q1 2026: 11,530 shares worth $32K. The stake represents ﹤0.01% of the portfolio and ranks #1626 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in ACIU as recently as Q4 2021.

GSA Capital Partners first reported a position in ACIU in Q4 2016 and has held it in 8 quarters since. The position peaked at $525K in Q1 2017. 46 funds tracked by Wall St. Rank hold ACIU as of Q1 2026.

GSA Capital Partners held 11,530 shares of AC Immune worth $32K as of Q1 2026.
AC Immune was a new GSA Capital Partners position in Q1 2026.
AC Immune made up ﹤0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1626 holding.
GSA Capital Partners first reported a position in AC Immune in Q4 2016 and has held it in 8 quarters since.
GSA Capital Partners's AC Immune position peaked at $525K in Q1 2017.
46 funds tracked by Wall St. Rank held AC Immune as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.